Ireland
--:--IST
Recruiting Observational

Effects of Surgery on Oral Frailty and Dysphagia in Patients With Obstructive Sleep Apnea

NCT07880067 · tracked via the Priya Life Science Taiwan tracker
Phase
Observational
Started
2026-06-12
Last updated
2026-10-19

Condition(s) studied

OSA - Obstructive Sleep ApneaDysphagiaOral Frailty

Investigational drug(s) / intervention(s)

Upper airway surgery for OSANon-surgical management

Upper airway surgery for OSA: Upper-airway surgical procedures chosen by the patient as part of routine care, including radiofrequency reduction of the soft palate or tongue base, palatine tonsillectomy, partial glossectomy, uvulopalatopharyngoplasty (UPPP), CO2 laser-assisted uvulopalatoplasty (LAUP), transoral robotic surgery (TORS) and related procedures. Not assigned by the study.

Non-surgical management: CPAP or other non-surgical management (e.g., oral appliance, weight control), or no treatment, as chosen by the patient as part of routine care. Not assigned by the study.

Study summary

Dysphagia is a commonly reported complaint among patients with obstructive sleep apnea (OSA), particularly those who have undergone upper-airway (oropharyngeal) surgery. However, how surgical treatment for OSA affects swallowing function and oral function (oral frailty) remains unclear.

This prospective cohort study recruits adults with moderate-to-severe OSA from the sleep medicine clinic of Kaohsiung Armed Forces General Hospital, Taiwan. Participants choose their own treatment as part of routine care; the study does not assign or influence treatment. Participants who undergo OSA surgery form the surgery group, and those who receive non-surgical treatment (e.g., CPAP) or no treatment form the non-surgical group. Swallowing difficulty (EAT-10) and oral frailty (seven oral hypofunction indicators) are assessed before treatment and at 1, 3, and 6 months after treatment.

Eligibility

Sex
ALL
Min age
20 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Diagnosed by a physician with moderate-to-severe obstructive sleep apnea (apnea-hypopnea index \>= 15 events/hour) * Aged 20 years or older * Willing to receive next-step treatment for obstructive sleep apnea * Willing to participate and provides written informed consent Exclusion Criteria: * Diagnosed with central sleep apnea * Neuromuscular disease (e.g., stroke, Parkinson's disease) * Diagnosed with oral cancer and currently receiving oral treatment

Primary outcome measure(s)

  • Change in swallowing difficulty measured by the Eating Assessment Tool-10 (EAT-10) — Baseline (before treatment), and 1, 3 and 6 months after treatment
    Chinese version of the EAT-10; 10 self-rated items scored 0 (no problem) to 4 (severe problem); total score 0-40, with higher scores indicating worse swallowing difficulty. A total score of 3 or more indicates swallowing problems.
  • Change in oral frailty (number of oral hypofunction indicators) — Baseline (before treatment), and 1, 3 and 6 months after treatment
    Number of the seven oral hypofunction indicators met (Minakuchi et al., 2018): poor oral hygiene, oral dryness, reduced occlusal force, reduced tongue-lip motor function, reduced tongue pressure, decreased masticatory function and deteriorated swallowing function. Range 0-7; meeting 3 or more indicators defines oral frailty (oral hypofunction).

Trial sites (1)

FacilityCityRegionStatus
Kaohsiung Armed Forces General Hospital Kaohsiung City Taiwan Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07880067 on ClinicalTrials.gov ↗ ← All trials in Taiwan